Pulse Biosciences (NASDAQ:PLSE) Trading Up 9.3% – Should You Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares were up 9.3% during mid-day trading on Friday . The stock traded as high as $17.63 and last traded at $17.62. Approximately 109,554 shares changed hands during trading, a decline of 46% from the average daily volume of 201,550 shares. The stock had previously closed at $16.12.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Tuesday, November 12th.

Pulse Biosciences Price Performance

The firm’s 50 day moving average price is $17.22 and its 200-day moving average price is $15.32.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company earned ($0.19) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% in the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after purchasing an additional 2,952 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Pulse Biosciences during the first quarter worth about $88,000. Quest Partners LLC acquired a new position in shares of Pulse Biosciences during the 2nd quarter worth about $91,000. Cetera Advisors LLC bought a new stake in shares of Pulse Biosciences in the 1st quarter valued at about $109,000. Finally, Rhumbline Advisers raised its position in shares of Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares during the period. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.